77242113PSO3001 Enrolling

Moderate to Severe Plaque Psoriasis Research Study (165 Weeks)

Treatment: Oral Age: 12 Years

Who Can Participate?

Adolescents and adults (≥12 years of age) with plaque psoriasis may be eligible to participate.


Inclusion Criteria:

      • Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks
      • Total body surface area (BSA) ≥10%
      • Moderate to severe plaque psoriasis
      • Candidate for phototherapy or systemic treatment for plaque psoriasis
      • Participants ≥12 to <18 years of age, body weight must be ≥40 kg


How Long Will The Study Last?

      • 165 weeks (24 visits)

Participants will receive either an investigational oral treatment (active study drug) or placebo.

Reimbursement for study-related expenses may be provided.

Participating Experts

Dr. Benjamin Barankin


Dr. Alim Devani


Dr. Anatoli Freiman


Dr. Chih-ho Hong


Dr. Wei Jing Loo


Dr. Vimal Prajapati


Dr. Maxwell Sauder


Dr. Sanjay Siddha


Dr. Darryl P. Toth


Dr. Geeta Yadav


Dr. Jensen Yeung


You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from

Last Update Posted: February 25, 2024

Official Title

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment ID



Janssen Research & Development, LLC

Study Description

  • Brief Summary:

    The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: JNJ-77242113
    Drug: JNJ-77242113
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    12 Years and older (Child)

  • Sexes Eligible for Study:


Inclusion Criteria:

Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
Total psoriasis area and severity index (PASI) >=12 at screening and baseline
Total investigator global assessment (IGA) >=3 at screening and baseline
Candidate for phototherapy or systemic treatment for plaque psoriasis
A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion Criteria:

Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study

Terms and Conditions –
Purpose of Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed to provide patients, family members, and members of the public current information about clinical research studies.


Learn More About


Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content